Shares of Regeneron Pharmaceuticals, Inc. REGN have gained 13.5% in the year so far against the industry’s decline of 2.8%.

The stock's rise snapped a five-day losing streak.

Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing ...

Regeneron, a leading biotech firm, is testing a drug called trevogrumab to preserve lean muscle while using these medications ...

Biotech company Regeneron Pharmaceuticals lost a bid on Friday to be held immune from allegations that it misused a patented ...

The co-founder of biotech firm Regeneron Pharmaceuticals (NASDAQ:REGN) said in a newspaper interview that popular weight-loss ...

Regeneron Pharmaceuticals (REGN) said it currently expects that financial results for the third quarter 2024 will include an acquired ...

Regeneron Pharmaceuticals expects to book a $56 million pretax charge related to collaboration and licensing agreements. The Westchester County, New York-based biotechnology company said Monday it ...

Regeneron Pharmaceuticals has purchased Quad’s shuttered printing plant in Saratoga Springs, sparking hopes for economic ...

The million-square-foot-plus complex was listed for sale earlier this year after its previous owner, Wisconsin-based ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

The co-founder of biotech firm Regeneron Pharmaceuticals (NASDAQ:REGN) said in a newspaper interview that popular weight-loss drugs could be harmful to people who lose too much muscle mass that ...